Immunogenicity, Efficacy and Safety of QazCovid-in® COVID-19 Vaccine

PHASE3CompletedINTERVENTIONAL
Enrollment

3,000

Participants

Timeline

Start Date

December 25, 2020

Primary Completion Date

April 26, 2021

Study Completion Date

July 11, 2021

Conditions
Covid19SARS-CoV InfectionVaccine Adverse Reaction
Interventions
BIOLOGICAL

QazCovid-in®-vaccine against COVID-19

QazCovid-in® (inactivated) Vaccine manufactured by Research Institute for Biological Safety Problems Republic of Kazakhstan

OTHER

Placebo

Placebo (sodium chloride buffs, solvent for the preparation of dosage forms for injection 0.9%)

Trial Locations (1)

080409

Research Institute for Biological Safety Problems Committee of Science of the Ministry of Education and Science of the Republic of Kazakhstan, Gvardeyskiy

All Listed Sponsors
collaborator

City polyclinic No. 4 of the of Almaty Ministry of Healthcare of the Republic of Kazakhstan

UNKNOWN

collaborator

Clinic of the International Institute of Postgraduate Education Ministry of Healthcare of the Republic of Kazakhstan

UNKNOWN

collaborator

City Multidisciplinary Hospital of Zhambyl Region Ministry of Healthcare of the Republic of Kazakhstan

UNKNOWN

lead

Research Institute for Biological Safety Problems

OTHER_GOV

NCT04691908 - Immunogenicity, Efficacy and Safety of QazCovid-in® COVID-19 Vaccine | Biotech Hunter | Biotech Hunter